News

ERC puts €680m into research
Enlarge image

FundingSwitzerlandEU

ERC puts €680m into research

24.01.2013 - The European Research Council (ERC) has awarded €680m to 302 top basic researchers in 24 EU countries.

The awards are part of the latest series of the ERC’s Advanced Grants, which give up to €2.5m per researcher to pursue ground-breaking ideas at the frontiers of knowledge. Life Science researchers were very successful in this call, bagging 37% of the total funding cake. However, at only 13%, the ERC grant’s success rate is very low compared to other funding programmes. The European Commission has proposed to expand the ERC's budget significantly in its 2014-2020 innovation programme Horizon 2020. Negotiations with the member states about the long-term EU budget including Horizon2020, however, were cancelled at the end of last year. This is why the ERC has now begun to extend its lobbying activities.

ERC representative Helga Nowotny, thus, for the first time attended the World Economic Forum (WEF) in Davos to embrace industry and policymakers. ”The health and wealth of future societies greatly depend on maintaining the long-term perspectives that science offers,“ said ERC chief Nowotny.."Investment in research, education and innovation is even more important in times of budgetary austerity, in Europe and elsewhere. Leaders from all fields, including business, understand this dynamic, but need to find novel ways of joining forces. We truly believe that science, as well as technology and innovation, will emerge as a common theme of interest to shape the agenda of the future decades”.

The idea to catalyse actions for putting science, technology and innovation on the global agenda has already started and is likely to be prominent in this year's forum. There is growing awareness amongst policy-makers worldwide and public research organisations, of the fact that globalisation of science offers unprecedented opportunities for cooperation. In Davos, one of the sessions will be devoted to how decision-makers, business, civil society and academia can join forces to build a new vision based on frontier research, scientific discoveries and innovation.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/erc-funds-researchers-with-eur680m.html

M&AIreland

31.03.2015 In its aim to expand its drug portfolio in orphan disease products, Horizon Pharma has acquired US company Hyperion Therapeutics for US$1.1bn in cash. The takeover entitles the UK biopharma to all of Hyperion’s common stock.

BusinessGermany

31.03.2015 Merck Serono has forged a US$941m (€876m) deal with US Intrexon for the development and commercialisation of CAR-T therapies. The new CAR-T projects are set to strengthen their R&D technology portfolio in immuno-oncology.

Stock MarketsFranceEU

27.03.2015 Europe is once more proving that it can be a good bet for biotech companies going public. A newly established EU-wide lobbying initiative could help the IPO boom on its way.

FinancingPoland

24.03.2015 Poland has announced the closing of a new venture capital fund at US$42m (€32m). The fund, which is the first of its kind in Poland, is dedicated to the Life Sciences with a strong connection to Central and Eastern Europe.

BioeconomyFranceSwedenGermanyNetherlandsFinland

23.03.2015 A BASF-led consortium aims to decrease bio-based production costs using industrial biotechnology. The Horizon2020 funded consortium is the sixth project of the SPIRE Public Private Partnership and has a budget of €14m.

Stock MarketsFranceSwedenUKNorwayIreland

20.03.2015 There are no signs of inertia creeping into the European biotech industry this spring. A total of eight IPOs are set to go public by the end of the year’s first quarter.

FinancingUKEU

17.03.2015 Pharma giants GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) will be key collaborators in a new global fund for dementia research to address the rising threat posed by dementia and Alzheimer’s disease.

FinancingFranceDenmarkSwedenGermany

19.03.2015 French venture capital firm Seventure Partners has raised a further €25m for its microbiome-focused Health for Life Capital Fund. It now stands at €100m.

EventsFranceEUSwitzerlandUKGermany

12.03.2015 With around 1,400 companies and 2,400 participants, the springtime counterpart of BIO-Europe enjoyed a successful premiere in France this year. The overall mood of the European biotech industry was positive, and the French hosts in particular reported new initiatives.

M&ABelgium

11.03.2015 Belgian cell-based therapeutics developer and CMO MaSTherCell SA has been acquired by US biotech Orgenesis Inc. for €23m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC1.28 EUR10.34%
  • BASILEA110.70 CHF2.31%
  • BIOTEST98.10 EUR2.29%

FLOP

  • PAION2.36 EUR-6.72%
  • MOLOGEN5.45 EUR-4.22%
  • WILEX3.01 EUR-2.90%

TOP

  • CYTOS1.43 CHF320.6%
  • MEDIGENE12.31 EUR189.6%
  • 4SC1.28 EUR64.1%

FLOP

  • MORPHOSYS58.81 EUR-21.3%
  • WILEX3.01 EUR-12.2%
  • BASILEA110.70 CHF-9.4%

TOP

  • SANTHERA93.75 CHF2214.8%
  • FORMYCON26.94 EUR271.6%
  • WILEX3.01 EUR220.2%

FLOP

  • CYTOS1.43 CHF-52.3%
  • MOLOGEN5.45 EUR-52.0%
  • PAION2.36 EUR-35.0%

No liability assumed, Date: 31.03.2015